Single-dose vaccination for chikungunya found safe, effective in first phase three trial: Lancet Study
Shortpedia
Content Team
Image Credit: pixabay
A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the first phase 3 trial of the preventive published in The Lancet journal. However, the researchers were unable to investigate whether the VLA1553 vaccine, developed by French biotech company Valneva, protects against subsequent disease since the study was not conducted in regions where chikungunya is endemic.
